Clinical Trial Update: Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

View source ↗

Summary

Datopotamab Deruxtecan has been approved for marketing in EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (datopotamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer | Status: APPROVED_FOR_MARKETING